Combined immunization with fusion genes of mutated E7 gene of human papillomavirus type 16 did not enhance antitumor effect

Journal of Gene Medicine

Volumn 7, Issue 6, 2005, Pages 696-707

  Pokorná, Dana ^a   Macková, Jana ^a   Dušková, Martina ^a   Rittich, Šimon ^a   Ludvíková, Viera ^a   Šmahel, Michal ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

Author keywords

E7 oncogene; Fusion genes; Gene gun; HPV; HSP; MHC class I

Indexed keywords

DNA VACCINE; HEAT SHOCK PROTEIN 70; HYBRID PROTEIN; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROTEIN E7; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNIZATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; FEMALE; GENE GUN; GENE MUTATION; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTECTION; TUMOR; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; ANTIGENS, NEOPLASM; BIOLISTICS; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; CELL TRANSFORMATION, VIRAL; FEMALE; HSP70 HEAT-SHOCK PROTEINS; IMMUNIZATION; INJECTIONS, SUBCUTANEOUS; LUNG NEOPLASMS; MICE; MICE, INBRED C57BL; MUTATION; NEOPLASMS, EXPERIMENTAL; NIH 3T3 CELLS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PLASMIDS; TIME FACTORS; TUMOR VIRUS INFECTIONS; VACCINATION; VACCINES, DNA;

HUMAN PAPILLOMAVIRUS TYPE 16;

EID: 21044433923     PISSN: 1099498X     EISSN: None     Source Type: Journal    
DOI: 10.1002/jgm.733     Document Type: Article

References (54)

1. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 1996; 56: 21-26.
2. Smahel M, Sima P, Ludvikova V, Marinov I, Pokorna D, Vonka V. Immunisation with modified HPV16 E7 genes against mouse oncogenic TC-1 cell sublines with downregulated expression of MHC class I molecules. Vaccine 2003; 21: 1125-1136.
3. Smahel M, Sima P, Ludvikova V, Vonka V. Modified HPV16 E7 genes as DNA vaccine against E7-containing oncogenic cells. Virology 2001; 281: 231-238.
4. Chen CA, Okayama H. Calcium phosphate-mediated gene transfer: a highly efficient transfection system for stably transforming cells with plasmid DNA. Biotechniques 1988; 6: 632-638.
5. Kaufmann AM, Gissmann L, Schreckenberger C, Qiao L. Cervical carcinoma cells transfected with the CD80 gene elicit a primary cytotoxic T lymphocyte response specific for HPV 16 E7 antigens. Cancer Gene Ther 1997; 4: 377-382.
6. Feltkamp MC, Smits HL, Vierboom MP, et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 1993; 23: 2242-2249.
7. Tindle RW, Fernando GJP, Sterling JC, Frazer IH. A 'public' T-helper epitope of the E7 transforming protein of human papillomavirus 16 provides cognate help for several E7 B-cell epitopes from cervical cancer-associated human papillomavirus genotypes. Proc Natl Acad Sci U S A 1991; 88: 5887-5891.
8. + T cells using an ELISPOT assay. J Immunol Methods 1995; 181: 45-54.
9. Murali-Krishna K, Altman JD, Suresh M, et al. Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. Immunity 1998; 8: 177-187.
10. Wu TC, Guarnieri FG, Staveley-O'Carroll KF, et al. Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proc Natl Acad Sci U S A 1995; 92: 11 671-11 675.
11. Nover L, Scharf KD. Heat stress proteins and transcription factors. Cell Mol Life Sci 1997; 53: 80-103.
12. Planelles L, Thomas MC, Alonso C, Lopez MC. DNA immunization with Trypanosoma cruzi HSP70 fused to the KMP11 protein elicits a cytotoxic and humoral immune response against the antigen and leads to protection. Infect Immun 2001; 69: 6558-6563.
13. Rico AI, Del Real G, Soto M, et al. Characterization of the immunostimulatory properties of Leishmania infantum HSP70 by fusion to the Escherichia coli maltose-binding protein in 3normal and nu/nu BALB/c mice. Infect Immunol 1998; 66: 347-352.
14. Suzue K, Young RA. Adjuvant-free hsp70 fusion protein system elicits humoral and cellular immune responses to HIV-1 p24. J Immunol 1996; 156: 873-879.
15. Udono H, Yamano T, Kawabata Y, Ueda M, Yui K. Generation of cytotoxic T lymphocytes by MHC class I ligands fused to heat shock cognate protein 70. Int Immunol 2001; 13: 1233-1242.
16. Huang Q, Richmond JF, Suzue K, Eisen HN, Young RA. In vivo cytotoxic T lymphocyte elicitation by mycobacterial heat shock protein 70 fusion proteins maps to a discrete domain and is CD4(+) T cell independent. J Exp Med 2000; 191: 403-408.
17. Anthony LS, Wu H, Sweet H, Turnnir C, Boux LJ, Mizzen LA. Priming of CD8+ CTL effector cells in mice by immunization with a stress protein-influenza virus nucleoprotein fusion molecule. Vaccine 1999; 17: 373-383.
18. Echeverria P, Dran G, Pereda G, et al. Analysis of the adjuvant effect of recombinant Leishmania infantum Hsp83 protein as a tool for vaccination. Immunol Lett 2001; 76: 107-110.
19. Kiang JG, Tsokos GC. Heat shock protein 70 kDa: molecular biology, biochemistry, and physiology. Pharmacol Ther 1998; 80: 183-201.
20. Cheng WF, Hung CF, Chai CY, et al. Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. J Clin Invest 2001; 108: 669-678.
21. Zwerschke W, Jansen-Durr P. Cell transformation by the E7 oncoprotein of human papillomavirus type 16: interactions with nuclear and cytoplasmic target proteins. Adv Cancer Res 2000; 78: 1-29.
22. Suzue K, Zhou X, Eisen HN, Young RA. Heat shock fusion proteins as vehicles for antigen delivery into the major histocompatibility complex class I presentation pathway. Proc Natl Acad Sci U S A 1997; 94: 13 146-13 151.
23. Shi W, Bu P, Liu J, Polack A, Fisher S, Qiao L. Human papillomavirus type 16 E7 DNA vaccine: mutation in the open reading frame of E7 enhances specific cytotoxic T-lymphocyte induction and antitumor activity. J Virol 1999; 73: 7877-7881.
24. Chu NR, Wu HB, Wu T, Boux LJ, Siegel MI, Mizzen LA. Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guerin (BCG) hsp65 and HPV16 E7. Clin Exp Immunol 2000; 121: 216-225.
25. Chen CH, Wang TL, Hung CF, et al. Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res 2000; 60: 1035-1042.
26. Cheng WF, Hung CF, Chai CY, et al. Enhancement of Sindbis virus self-replicating RNA vaccine potency by linkage of Mycobacterium tuberculosis heat shock protein 70 gene to an antigen gene. J Immunol 2001; 166: 6218-6226.
27. Manjili MH, Wang XY, Park J, Facciponte JG, Repasky EA, Subjeck Jr. Immunotherapy of cancer using hear shock proteins. Front Biosci 2002; 7: d43-52.
28. Cho BK, Palliser D, Guillen E, et al. A proposed mechanism for the induction of cytotoxic T lymphocyte production by heat shock fusion proteins. Immunity 2000; 12: 263-272.
29. Liu DW, Tsao YP, Kung JT, et al. Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer. J Virol 2000; 74: 2888-2894.
30. Hsu KF, Hung CF, Cheng WF, et al. Enhancement of suicidal DNA vaccine potency by linking Mycobacterium tuberculosis heat shock protein 70 to an antigen. Gene Ther 2001; 8: 376-383.
31. Hung CF, Wu TC. Improving DNA vaccine potency via modification of professional antigen presenting cells. Curr Opin Mol Ther 2003; 5: 20-24.
32. Goldstone SE, Palefsky JM, Winnett MT, Neefe Jr. Activity of HspE7, a novel immunotherapy, in patients with anogenital warts. Dis Colon Rectum 2002; 45: 502-507.
33. Hunt S. Technology evaluation: HspE7, StressGen Biotechnologies Corp. Curr Opin Mol Ther 2001; 3: 413-417.
34. Cheng WF, Hung CF, Lin KY, et al. CD8+ T cells, NK cells and IFN-gamma are important for control of tumor with downregulated MHC class I expression by DNA vaccination. Gene Ther 2003; 10: 1311-1320.
35. Planelles L, Thomas M, Pulgar M, Maranon C, Grabbe S, Lopez MC. Trypanosoma cruzi heat-shock protein-70 kDa, alone or fused to the parasite KMP11 antigen, induces functional maturation of murine dendritic cells. Immunol Cell Biol 2002; 80: 241-247.
36. De Marco F, Hallez S, Brulet JM, et al. DNA vaccines against HPV-16 E7-expressing tumour cells. Anticancer Res 2003; 23: 1449-1454.
37. Chu NR. Therapeutic vaccination for the treatment of mucosotropic human papillomavirus-associated disease. Expert Opin Biol Ther 2003; 3: 477-486.
38. Sehr P, Zumbach K, Pawlita M. A generic capture ELISA for recombinant proteins fused to glutathione S-transferase: validation for HPV serology. J Immunol Methods 2001; 253: 153-162.
39. Sehr P, Muller M, Hopfl R, Widschwendter A, Pawlita M. HPV antibody detection by ELISA with capsid protein L1 fused to glutathione S-transferase. J Virol Methods 2002; 106: 61-70.
40. Smahel M, Pokorna D, Mackova J, Vlasak J. Enhancement of immunogenicity of HPV16 E7 oncogene by fusion with E. coli β-glucuronidase. J Gene Med. 2005; in press.
41. Michel N, Osen W, Gissmann L, Schumacher TN, Zentgraf H, Muller M. Enhanced immunogenicity of HPV 16 E7 fusion proteins in DNA vaccination. Virology 2002; 294: 47-59.
42. Cheng WF, Hung CF, Pai SI, et al. Repeated DNA vaccinations elicited qualitatively different cytotoxic T lymphocytes and improved protective antitumor effects. J Biomed Sci 2002; 9: 675-687.
43. Zhu D, Stevenson FK. DNA gene fusion vaccines against cancer. Curr Opin Mol Ther 2002; 4: 41-48.
44. Kim JW, Hung CF, Juang J, et al. Comparison of HPV DNA vaccines employing intracellular targeting strategies. Gene Ther. 2005; in press.
45. Morel PA, Falkner D, Plowey J, Larregina AT, Falo LD. DNA immunisation: altering the cellular localisation of expressed protein and the immunisation route allows manipulation of the immune response. Vaccine 2004; 22: 447-456.
46. Smotkin D, Wettstein FO. The major human papillomavirus protein in cervical cancers is a cytoplasmic phosphoprotein. J Virol 1987; 61: 1686-1689.
47. Bermudez-Humaran LG, Cortes-Perez NG, Le Loir Y, et al. Fusion to a carrier protein and a synthetic propeptide enhances E7 HPV-16 production and secretion in Lactococcus lactis. Biotechnol Prog 2003; 19: 1101-1104.
48. Daemen T, Regts J, Holtrop M, Wilschut J. Immunization strategy against cervical cancer involving an alphavirus vector expressing high levels of a stable fusion protein of human papillomavirus 16 E6 and E7. Gene Ther 2002; 9: 85-94.
49. Reinstein E, Scheffner M, Oren M, Ciechanover A, Schwartz A. Degradation of the E7 human papillomavirus oncoprotein by the ubiquitin-proteasome system: targeting via ubiquitination of the N-terminal residue. Oncogene 2000; 19: 5944-5950.
50. Liu WJ, Zhao KN, Gao FG, Leggatt GR, Fernando GJ, Frazer IH. Polynucleotide viral vaccines: codon optimisation and ubiquitin conjugation enhances prophylactic and therapeutic efficacy. Vaccine 2001; 20: 862-869.
51. Fuller DH, Haynes Jr. A qualitative progression in HIV type 1 glycoprotein 120-specific cytotoxic cellular and humoral immune responses in mice receiving a DNA-based glycoprotein 120 vaccine. AIDS Res Hum Retroviruses 1994; 10: 1433-1441.
52. MacGregor RR, Boyer JD, Ugen KE, et al. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J Infect Dis 1998; 178: 92-100.
53. Fu TM, Guan L, Friedman A, et al. Dose dependence of CTL precursor frequency induced by a DNA vaccine and correlation with protective immunity against influenza virus challenge. J Immunol 1999; 162: 4163-4170.
54. Chen CH, Ji H, Suh KW, Choti MA, Pardoll DM, Wu TC. Gene gun-mediated DNA vaccination induces antitumor immunity against human papillomavirus type 16 E7-expressing murine tumor metastases in the liver and lungs. Gene Ther 1999; 6: 1972-1981.